<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01364363</url>
  </required_header>
  <id_info>
    <org_study_id>SIRB#13-6190</org_study_id>
    <nct_id>NCT01364363</nct_id>
  </id_info>
  <brief_title>Unrelated Donor Stem Cell Transplantation</brief_title>
  <official_title>Allogeneic Hematopoietic Progenitor Cell Transplantation From Unrelated Donors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scripps Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Scripps Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide an opportunity for patients with malignancies or bone
      marrow failure states who lack a suitable sibling donor to undergo allogeneic hematopoietic
      progenitor cell transplantation using cells from unrelated individuals or cord blood
      registries.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone Marrow and Peripheral Blood Chimerism</measure>
    <time_frame>30 days post-transplant</time_frame>
    <description>Percent of donor and host cells in peripheral blood and bone marrow will be measured by short tandem repeat (STR) testing and/or standard cytogenetic testing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone Marrow and Peripheral Blood Chimerism</measure>
    <time_frame>100 days post-transplant</time_frame>
    <description>Percent of donor and host cells in peripheral blood and bone marrow will be measured by short tandem repeat (STR) testing and/or standard cytogenetic testing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone Marrow and Peripheral Blood Chimerism</measure>
    <time_frame>365 days post-transplant</time_frame>
    <description>Percent of donor and host cells in peripheral blood and bone marrow will be measured by short tandem repeat (STR) testing and/or standard cytogenetic testing.</description>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Severe Aplastic Anemia</condition>
  <condition>Paroxysmal Nocturnal Hemoglobinuria</condition>
  <condition>Acute Myelogenous Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myeloproliferative Syndromes</condition>
  <condition>Chronic Myelogenous Leukemia</condition>
  <condition>Hodgkin's Lymphoma</condition>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Small Lymphocytic Lymphoma</condition>
  <condition>Large Granulocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Total Body Irradiation/VP16</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Acute Leukemias, Myelodysplastic syndromes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cytoxan/Total Body Irradiation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Chronic Leukemias, Bone Marrow Failure States, Lymphomas, Hodgkin's Disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Busulfan/Cytoxan</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Acute Leukemia, Myelodysplastic syndromes, Chronic Leukemias, Bone Marrow Failure states</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BEAM (BCNU, etoposide, Ara-C, melphalan)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Lymphomas, Hodgkin's Disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Total Lymphoid Irradiation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>For patients with Multiple Myeloma, or prior autologous transplantation, or age in excess of 55</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cladribine/Melphalan</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>For patients with Multiple Myeloma, or prior autologous transplantation, or age in excess of 55</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FLAG (fludarabine, Ara-C, G-CSF)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>For patients undergoing a second allogeneic transplant</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic transplantation</intervention_name>
    <description>Allogeneic transplantation with matched unrelated donors</description>
    <arm_group_label>Total Body Irradiation/VP16</arm_group_label>
    <arm_group_label>Cytoxan/Total Body Irradiation</arm_group_label>
    <arm_group_label>Busulfan/Cytoxan</arm_group_label>
    <arm_group_label>BEAM (BCNU, etoposide, Ara-C, melphalan)</arm_group_label>
    <arm_group_label>Total Lymphoid Irradiation</arm_group_label>
    <arm_group_label>Cladribine/Melphalan</arm_group_label>
    <arm_group_label>FLAG (fludarabine, Ara-C, G-CSF)</arm_group_label>
    <other_name>MUD transplant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt; 18 years of Age

          -  &lt; 70 years

          -  ECOG performance status 0, 1 or 2

          -  Left Ventricular Ejection Fraction &gt; 30%

          -  Creatinine clearance &gt; 40ml/min

          -  Transaminases &lt; 2X normal

          -  Total bilirubin &lt; 2X normal

          -  HIV seronegativity

          -  Weight &lt; 70kg for cord blood transplantation

          -  Ability to cover the cost of the transplant, necessary medications, and
             transportation/housing.

          -  Caregiver must be available while outpatient

        Exclusion Criteria:

          -  Greater than one antigen mismatch at HLA-A, B, C or DR plus one allele mismatch at
             HLA-A, B, C or DR
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey W. Andrey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scripps Clinic Medical Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carol Burian</last_name>
    <phone>858-554-2845</phone>
    <email>Burian.Carol@scrippshealth.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Scripps Green Hospital</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Burian</last_name>
      <phone>858-554-2845</phone>
      <email>Burian.Carol@scrippshealth.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey W. Andrey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.scripps.org/services/cancer-care/research</url>
  </link>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2011</study_first_submitted>
  <study_first_submitted_qc>June 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2011</study_first_posted>
  <last_update_submitted>December 5, 2013</last_update_submitted>
  <last_update_submitted_qc>December 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Scripps Health</investigator_affiliation>
    <investigator_full_name>Jeffrey Andrey, MD</investigator_full_name>
    <investigator_title>Director, Unrelated Donor Transplantation</investigator_title>
  </responsible_party>
  <keyword>Transplant</keyword>
  <keyword>Allogeneic</keyword>
  <keyword>Allogeneic transplant</keyword>
  <keyword>Unrelated donor transplant</keyword>
  <keyword>MUD</keyword>
  <keyword>HSCT</keyword>
  <keyword>Stem cell transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Hemoglobinuria</mesh_term>
    <mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

